Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9365789 | 1.00 | KMT2A (0.72) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8342494 | 0.89 | LMNA (0.75) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9369302 | 0.88 | LMNA (0.78) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9365388 | 0.87 | LMNA (0.72) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4429170 | 0.87 | LMNA (0.67) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8342323 | 0.87 | LMNA (0.72) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9365729 | 0.87 | LMNA (0.72) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8345917 | 0.85 | LMNA (0.78) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8342786 | 0.84 | LMNA (0.68) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8343305 | 0.84 | LMNA (0.68) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | KMT2A 3596/4885LMNA 4428/4885MEN1 419/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | KMT2A 3596/4885LMNA 4428/4885MEN1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.